Oslo, Norway, March 9, 2022 /PRNewswire/ — Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotechnology company focused on CD37-targeted therapies for hematological cancers and immune diseases, announces that an e-poster regarding Alpha37, titled “Alpha Therapy targeted with 212Pb-NNV003 in treatment of NHL,” will be presented at the 2022 American Association of Cancer Research (AACR) Annual Meeting taking place April 8-13 at New Orleans, United States.

Electronic poster data shows that a single injection of 212Pb-NNV003, or Alpha37, is safe and effective for the treatment of CD37-positive chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) in mouse models. Promising efficacy in ibrutinib-resistant and ibrutinib-responsive CLL models was observed and Alpha37 treatment was superior to ibrutinib and oblinutuzumab, confirming that further clinical development is warranted. This data has already been presented at the company’s R&D Day in November 2021.

Alpha37 was developed as a targeted alpha radioimmunotherapy where the CD37-specific antibody NNV003 is coupled to the isotope generating alpha particles 212Pb for the treatment of NHL and CLL. Despite the availability of current treatments, most patients with these diseases inevitably relapse, meaning there is a significant unmet need for new alternative therapies.

Jostein DahleCo-founder and CSO from Nordic Nanovector, commented: “The preclinical data we have amassed on Alpha37 brings us closer to our goal of filing an IND to begin human clinical trials. We are focusing on high-risk and/or ibrutinib-resistant/refractory CLL as an indication of entry, but we believe there is a broader unmet need beyond that that Alpha37 may be able to satisfy. We look forward to the further development of this next-generation targeted anti-CD37 alpha radioimmunoconjugate .

For more information, please contact:

IR requests

Malene Brondberg, Chief Financial Officer
Cellular: +44 7561 431 762
Email: [email protected]

Media inquiries

swallow mark/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: [email protected]

About Nordic Nanovector:

Nordic Nanovector is committed to developing and delivering innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of CD37-targeting therapies for hematological cancers and immune diseases. Nordic Nanovector’s lead clinical-stage candidate is betalutin®, a new radioimmunotherapy targeting CD37 designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with significant unmet medical need, representing a growing market that is expected to be worth close to $27 billion by 2029. Nordic Nanovector retains worldwide marketing rights to Betalutin® and intends to participate actively in the marketing of Betalutin® in the United States and other major markets. Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainties and changes in circumstances because they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on business, finances and the state and results of operations. The terms “plans”, “assumes”, “believes”, “may”, “could”, “estimates”, “expects”, “plans”, “intends”, “may”, ” could”, “plans”, “should”, “projects”, “targets”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify the statements prospective. These forward-looking statements are not historical facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with the execution of Nordic Nanovector’s strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector’s product candidates. Nordic Nanovector, ongoing and future clinical trials and expected trial results, the ability to commercialize Betalutin®, technological changes and new products in the potential market and industry of Nordic Nanovector, Nordic’s freedom to operate Nanovector (competing patents) with respect to the products it develops, the ability to develop new products and improve existing products, the impact of competition, changes in general economic and industry; and legislative, regulatory and political factors. No assurance can be given that these expectations will prove to be correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to a disclosure requirement under Sections 4-2 and 5-12 of the Securities Trading Act.

CONTACT:

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-announces-presentation-of-preclinical-data-on-alpha37–at-the-american-association,c3521293